{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T07:00:21Z","timestamp":1791961221656,"version":"4.3.4"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>EBV elicits primary CD8+ T cell responses that, by T cell cloning from infectious mononucleosis (IM) patients, appear skewed toward immediate early (IE) and some early (E) lytic cycle proteins, with late (L) proteins rarely targeted. However, L Ag-specific responses have been detected regularly in polyclonal T cell cultures from long-term virus carriers. To resolve this apparent difference between responses to primary and persistent infection, 13 long-term carriers were screened in ex vivo IFN-\u03b3 ELISPOT assays using peptides spanning the two IE, six representative E, and seven representative L proteins. This revealed memory CD8 responses to 44 new lytic cycle epitopes that straddle all three protein classes but, in terms of both frequency and size, maintain the IE &amp;gt; E &amp;gt; L hierarchy of immunodominance. Having identified the HLA restriction of 10 (including 7 L) new epitopes using memory CD8+ T cell clones, we looked in HLA-matched IM patients and found such reactivities but typically at low levels, explaining why they had gone undetected in the original IM clonal screens. Wherever tested, all CD8+ T cell clones against these novel lytic cycle epitopes recognized lytically infected cells naturally expressing their target Ag. Surprisingly, however, clones against the most frequently recognized L Ag, the BNRF1 tegument protein, also recognized latently infected, growth-transformed cells. We infer that BNRF1 is also a latent Ag that could be targeted in T cell therapy of EBV-driven B-lymphoproliferative disease.<\/jats:p>","DOI":"10.4049\/jimmunol.1301629","type":"journal-article","created":{"date-parts":[[2013,10,22]],"date-time":"2013-10-22T02:13:25Z","timestamp":1382408005000},"page":"5398-5409","source":"Crossref","is-referenced-by-count":66,"title":["CD8+ T Cell Responses to Lytic EBV Infection: Late Antigen Specificities as Subdominant Components of the Total Response"],"prefix":"10.1093","volume":"191","author":[{"given":"Rachel J M","family":"Abbott","sequence":"first","affiliation":[{"name":"School of Cancer Sciences and Medical Research Council Centre for Immune Regulation, College of Medical and Dental Sciences, University of Birmingham , Birmingham B15 2TT,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura L","family":"Quinn","sequence":"additional","affiliation":[{"name":"School of Cancer Sciences and Medical Research Council Centre for Immune Regulation, College of Medical and Dental Sciences, University of Birmingham , Birmingham B15 2TT,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison M","family":"Leese","sequence":"additional","affiliation":[{"name":"School of Cancer Sciences and Medical Research Council Centre for Immune Regulation, College of Medical and Dental Sciences, University of Birmingham , Birmingham B15 2TT,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry M","family":"Scholes","sequence":"additional","affiliation":[{"name":"School of Cancer Sciences and Medical Research Council Centre for Immune Regulation, College of Medical and Dental Sciences, University of Birmingham , Birmingham B15 2TT,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Pachnio","sequence":"additional","affiliation":[{"name":"School of Cancer Sciences and Medical Research Council Centre for Immune Regulation, College of Medical and Dental Sciences, University of Birmingham , Birmingham B15 2TT,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan B","family":"Rickinson","sequence":"additional","affiliation":[{"name":"School of Cancer Sciences and Medical Research Council Centre for Immune Regulation, College of Medical and Dental Sciences, University of Birmingham , Birmingham B15 2TT,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2013,12,1]]},"reference":[{"key":"2025032406023232100_r1","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1084\/jem.187.9.1395","article-title":"Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus in vivo","volume":"187","author":"Callan","year":"1998","journal-title":"J. Exp. Med."},{"key":"2025032406023232100_r2","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1146\/annurev.immunol.25.022106.141553","article-title":"Cellular responses to viral infection in humans: lessons from Epstein-Barr virus","volume":"25","author":"Hislop","year":"2007","journal-title":"Annu. Rev. Immunol."},{"key":"2025032406023232100_r3","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1074-7613(00)80622-6","article-title":"EBV persistence in memory B cells in vivo","volume":"9","author":"Babcock","year":"1998","journal-title":"Immunity"},{"key":"2025032406023232100_r4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev.med.56.082103.104727","article-title":"Post-transplant lymphoproliferative disorders","volume":"56","author":"Gottschalk","year":"2005","journal-title":"Annu. Rev. Med."},{"key":"2025032406023232100_r5","article-title":"Epstein-Barr Virus","volume":"5","author":"Rickinson","year":"2007","journal-title":"In Fields\u2019 Virology"},{"key":"2025032406023232100_r6","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1084\/jem.20041542","article-title":"CD8+ immunodominance among Epstein-Barr virus lytic cycle antigens directly reflects the efficiency of antigen presentation in lytically infected cells","volume":"201","author":"Pudney","year":"2005","journal-title":"J. Exp. Med."},{"key":"2025032406023232100_r7","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1084\/jem.185.9.1605","article-title":"Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response","volume":"185","author":"Steven","year":"1997","journal-title":"J. Exp. Med."},{"key":"2025032406023232100_r8","doi-asserted-by":"crossref","first-page":"4450","DOI":"10.4049\/jimmunol.167.8.4450","article-title":"Differential evolution and stability of epitope-specific CD8(+) T cell responses in EBV infection","volume":"167","author":"Catalina","year":"2001","journal-title":"J. Immunol."},{"key":"2025032406023232100_r9","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1084\/jem.20011692","article-title":"Epitope-specific evolution of human CD8(+) T cell responses from primary to persistent phases of Epstein-Barr virus infection","volume":"195","author":"Hislop","year":"2002","journal-title":"J. Exp. Med."},{"key":"2025032406023232100_r10","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1086\/491741","article-title":"Differential targeting and shifts in the immunodominance of Epstein-Barr virus\u2013specific CD8 and CD4 T cell responses during acute and persistent infection","volume":"192","author":"Woodberry","year":"2005","journal-title":"J. Infect. Dis."},{"key":"2025032406023232100_r11","doi-asserted-by":"crossref","first-page":"e1000490","DOI":"10.1371\/journal.ppat.1000490","article-title":"Stage-specific inhibition of MHC class I presentation by the Epstein-Barr virus BNLF2a protein during virus lytic cycle","volume":"5","author":"Croft","year":"2009","journal-title":"PLoS Pathog."},{"key":"2025032406023232100_r12","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1084\/jem.20070256","article-title":"A CD8+ T cell immune evasion protein specific to Epstein-Barr virus and its close relatives in Old World primates","volume":"204","author":"Hislop","year":"2007","journal-title":"J. Exp. Med."},{"key":"2025032406023232100_r13","doi-asserted-by":"crossref","first-page":"e1000255","DOI":"10.1371\/journal.ppat.1000255","article-title":"The Epstein-Barr virus G-protein-coupled receptor contributes to immune evasion by targeting MHC class I molecules for degradation","volume":"5","author":"Zuo","year":"2009","journal-title":"PLoS Pathog."},{"key":"2025032406023232100_r14","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1128\/JVI.01608-10","article-title":"The Epstein-Barr virus-encoded BILF1 protein modulates immune recognition of endogenously processed antigen by targeting major histocompatibility complex class I molecules trafficking on both the exocytic and endocytic pathways","volume":"85","author":"Zuo","year":"2011","journal-title":"J. Virol."},{"key":"2025032406023232100_r15","doi-asserted-by":"crossref","first-page":"e1002704","DOI":"10.1371\/journal.ppat.1002704","article-title":"The EBV immunoevasins vIL-10 and BNLF2a protect newly infected B cells from immune recognition and elimination","volume":"8","author":"Jochum","year":"2012","journal-title":"PLoS Pathog."},{"key":"2025032406023232100_r16","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1073\/pnas.0611128104","article-title":"Host shutoff during productive Epstein-Barr virus infection is mediated by BGLF5 and may contribute to immune evasion","volume":"104","author":"Rowe","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025032406023232100_r17","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1182\/blood.V90.6.2390","article-title":"Downregulation of TAP1 in B lymphocytes by cellular and Epstein-Barr virus-encoded interleukin-10","volume":"90","author":"Zeidler","year":"1997","journal-title":"Blood"},{"key":"2025032406023232100_r18","doi-asserted-by":"crossref","first-page":"4872","DOI":"10.1128\/jvi.69.8.4872-4879.1995","article-title":"Specific cytotoxic T lymphocytes recognize the immediate-early transactivator Zta of Epstein-Barr virus","volume":"69","author":"Bogedain","year":"1995","journal-title":"J. Virol."},{"key":"2025032406023232100_r19","doi-asserted-by":"crossref","first-page":"8644","DOI":"10.1128\/JVI.72.11.8644-8649.1998","article-title":"Immediate-early transactivator Rta of Epstein-Barr virus (EBV) shows multiple epitopes recognized by EBV-specific cytotoxic T lymphocytes","volume":"72","author":"Pepperl","year":"1998","journal-title":"J. Virol."},{"key":"2025032406023232100_r20","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1002\/1521-4141(200009)30:9<2531::AID-IMMU2531>3.0.CO;2-O","article-title":"A global appraisal of immunodominant CD8 T cell responses to Epstein-Barr virus and cytomegalovirus by bulk screening","volume":"30","author":"Saulquin","year":"2000","journal-title":"Eur. J. Immunol."},{"key":"2025032406023232100_r21","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1084\/jem.184.5.1791","article-title":"T cell response to Epstein-Barr virus transactivators in chronic rheumatoid arthritis","volume":"184","author":"Scotet","year":"1996","journal-title":"J. Exp. Med."},{"key":"2025032406023232100_r22","doi-asserted-by":"crossref","first-page":"3769","DOI":"10.1016\/S0264-410X(01)00085-8","article-title":"Contrasting Epstein-Barr virus-specific cytotoxic T cell responses to HLA A2-restricted epitopes in humans and HLA transgenic mice: implications for vaccine design","volume":"19","author":"Bharadwaj","year":"2001","journal-title":"Vaccine"},{"key":"2025032406023232100_r23","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.4049\/jimmunol.162.5.3063","article-title":"EBV structural antigens, gp350 and gp85, as targets for ex vivo virus-specific CTL during acute infectious mononucleosis: potential use of gp350\/gp85 CTL epitopes for vaccine design","volume":"162","author":"Khanna","year":"1999","journal-title":"J. Immunol."},{"key":"2025032406023232100_r24","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/1521-4141(200103)31:3<708::AID-IMMU708>3.0.CO;2-5","article-title":"Frequent recognition of BCRF1, a late lytic cycle protein of Epstein-Barr virus, in the HLA-B*2705 context: evidence for a TAP-independent processing","volume":"31","author":"Saulquin","year":"2001","journal-title":"Eur. J. Immunol."},{"key":"2025032406023232100_r25","doi-asserted-by":"crossref","first-page":"12821","DOI":"10.1128\/JVI.05742-11","article-title":"Persistent infection drives the development of CD8+ T cells specific for late lytic infection antigens in lymphocryptovirus-infected macaques and Epstein-Barr virus-infected humans","volume":"85","author":"Orlova","year":"2011","journal-title":"J. Virol."},{"key":"2025032406023232100_r26","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.4049\/jimmunol.162.3.1827","article-title":"A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers","volume":"162","author":"Tan","year":"1999","journal-title":"J. Immunol."},{"key":"2025032406023232100_r27","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1093\/emboj\/19.12.3080","article-title":"The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators","volume":"19","author":"Feederle","year":"2000","journal-title":"EMBO J."},{"key":"2025032406023232100_r28","doi-asserted-by":"crossref","first-page":"561","DOI":"10.4049\/jimmunol.1300292","article-title":"HLA peptide length preferences control CD8+ T cell responses","volume":"191","author":"Rist","year":"2013","journal-title":"J. Immunol."},{"key":"2025032406023232100_r29","doi-asserted-by":"crossref","first-page":"6351","DOI":"10.4049\/jimmunol.162.11.6351","article-title":"Selection and long-term persistence of reactive CTL clones during an EBV chronic response are determined by avidity, CD8 variable contribution compensating for differences in TCR affinities","volume":"162","author":"Couedel","year":"1999","journal-title":"J. Immunol."},{"key":"2025032406023232100_r30","doi-asserted-by":"crossref","first-page":"9068","DOI":"10.1128\/JVI.00141-09","article-title":"Upregulation of interleukin 7 receptor alpha and programmed death 1 marks an epitope-specific CD8+ T-cell response that disappears following primary Epstein-Barr virus infection","volume":"83","author":"Sauce","year":"2009","journal-title":"J. Virol."},{"key":"2025032406023232100_r31","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.it.2011.11.005","article-title":"Memory T cell inflation: understanding cause and effect","volume":"33","author":"O\u2019Hara","year":"2012","journal-title":"Trends Immunol."},{"key":"2025032406023232100_r32","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1046\/j.1365-2567.1999.00901.x","article-title":"Large clonal expansions of human virus-specific memory cytotoxic T lymphocytes within the CD57+ CD28\u2212 CD8+ T-cell population","volume":"98","author":"Weekes","year":"1999","journal-title":"Immunology"},{"key":"2025032406023232100_r33","doi-asserted-by":"crossref","first-page":"16286","DOI":"10.1073\/pnas.0407320101","article-title":"Proteins of purified Epstein-Barr virus","volume":"101","author":"Johannsen","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025032406023232100_r34","first-page":"6219","article-title":"Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin\u2019s disease patients: implications for a T-cell-based therapy","volume":"61","author":"Chapman","year":"2001","journal-title":"Cancer Res."},{"key":"2025032406023232100_r35","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0022-1759(01)00416-1","article-title":"Use of overlapping peptide mixtures as antigens for cytokine flow cytometry","volume":"255","author":"Maecker","year":"2001","journal-title":"J. Immunol. Methods"},{"key":"2025032406023232100_r36","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0022-1759(02)00541-0","article-title":"Comparison of overlapping peptide sets for detection of antiviral CD8 and CD4 T cell responses","volume":"275","author":"Draenert","year":"2003","journal-title":"J. Immunol. Methods"},{"key":"2025032406023232100_r37","doi-asserted-by":"crossref","first-page":"92","DOI":"10.4049\/jimmunol.1100590","article-title":"Cytotoxic CD4+ T cell responses to EBV contrast with CD8 responses in breadth of lytic cycle antigen choice and in lytic cycle recognition","volume":"187","author":"Long","year":"2011","journal-title":"J. Immunol."},{"key":"2025032406023232100_r38","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.micinf.2009.12.001","article-title":"Immune responses to Epstein-Barr virus: molecular interactions in the virus evasion of CD8+ T cell immunity","volume":"12","author":"Rowe","year":"2010","journal-title":"Microbes Infect."},{"key":"2025032406023232100_r39","first-page":"621","article-title":"Identification of Epstein-Barr virus lytic activity in post-transplantation lymphoproliferative disease","volume":"9","author":"Montone","year":"1996","journal-title":"Mod. Pathol."},{"key":"2025032406023232100_r40","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/annonc\/5.suppl_1.S113","article-title":"Epstein-Barr virus latent and replicative gene expression in post-transplant lymphoproliferative disorders and AIDS-related non-Hodgkin\u2019s lymphomas. French Study Group of Pathology for HIV-associated Tumors","volume":"5","author":"Rea","year":"1994","journal-title":"Ann. Oncol."},{"key":"2025032406023232100_r41","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1034\/j.1399-3062.2001.003002060.x","article-title":"The Epstein-Barr virus and post-transplant lymphoproliferative disease: interplay of immunosuppression, EBV, and the immune system in disease pathogenesis","volume":"3","author":"Tanner","year":"2001","journal-title":"Transpl. Infect. Dis."},{"key":"2025032406023232100_r42","doi-asserted-by":"crossref","first-page":"9435","DOI":"10.1128\/JVI.00473-06","article-title":"Epstein-Barr virus BNRF1 protein allows efficient transfer from the endosomal compartment to the nucleus of primary B lymphocytes","volume":"80","author":"Feederle","year":"2006","journal-title":"J. Virol."},{"key":"2025032406023232100_r43","doi-asserted-by":"crossref","first-page":"e1002376","DOI":"10.1371\/journal.ppat.1002376","article-title":"EBV tegument protein BNRF1 disrupts DAXX-ATRX to activate viral early gene transcription","volume":"7","author":"Tsai","year":"2011","journal-title":"PLoS Pathog."},{"key":"2025032406023232100_r44","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1172\/JCI10590","article-title":"CD8(+) T-cell selection, function, and death in the primary immune response in vivo","volume":"106","author":"Callan","year":"2000","journal-title":"J. Clin. Invest."},{"key":"2025032406023232100_r45","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1084\/jem.20051287","article-title":"Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins","volume":"203","author":"Adhikary","year":"2006","journal-title":"J. Exp. Med."},{"key":"2025032406023232100_r46","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejcb.2011.01.007","article-title":"The role of virus-specific CD4+ T cells in the control of Epstein-Barr virus infection","volume":"91","author":"Mautner","year":"2012","journal-title":"Eur. J. Cell Biol."},{"key":"2025032406023232100_r47","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0952791502000031","article-title":"Cross priming or direct priming: is that really the question?","volume":"15","author":"Norbury","year":"2003","journal-title":"Curr. Opin. Immunol."}],"container-title":["The Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/191\/11\/5398\/62510599\/1301629.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/191\/11\/5398\/62510599\/1301629.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T15:01:27Z","timestamp":1742914887000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jimmunol\/article\/191\/11\/5398\/7989725"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,1]]},"references-count":47,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,12,1]]}},"URL":"https:\/\/doi.org\/10.4049\/jimmunol.1301629","relation":{},"ISSN":["0022-1767","1550-6606"],"issn-type":[{"value":"0022-1767","type":"print"},{"value":"1550-6606","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2013,12]]},"published":{"date-parts":[[2013,12,1]]}}}